Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Male dogs more likely to develop contagious oro-nasal cancer
"We think it's important to consider CTVT as a possible diagnosis for oro-nasal tumours in dogs" - Dr Andrea Strakova.
Researchers believe this may be due to behavioural differences.

Male dogs are four to five times more likely to develop a contagious cancer on their nose and mouth than female dogs, a study from the University of Cambridge has found.

Canine Transmissible Venereal Tumour (CTVT) is spread when dogs come into contact. An infectious cancer, the living cancer cells are able to transplant from one dog into another.

CTVT affects the genitalia of dogs most commonly, and is often transmitted during mating, however, the cancer can also affect a dog's nose, mouth and skin. The oro-nasal form of CTVT is transmitted through the sniffing or licking dogs' genitalia.

Dr Andrea Strakova, first author of the paper, explained: “We found that a very significant proportion of the nose or mouth tumours of canine transmissible cancer were in male dogs.

“We think this is because male dogs may have a preference for sniffing or licking the female genitalia, compared to vice versa. 

“The female genital tumours may also be more accessible for sniffing and licking, compared to the male genital tumours.”

In the study, researchers reviewed a database of almost 2,000 CTVT cases worldwide, finding that only 32 cases affected the nose and mouth. Of these cases, 27 were male dogs.

Dr Strakova discussed the importance of veterinary surgeons being aware of oro-nasal CTVT:
“Although canine transmissible cancer can be diagnosed and treated fairly easily, veterinarians in the UK may not be familiar with the signs of the disease because it is very rare here.

“We think it’s important to consider CTVT as a possible diagnosis for oro-nasal tumours in dogs. Treatment is very effective, using single agent Vincristine chemotherapy, and the vast majority of dogs recover.”

Signs of the oro-nasal form of CTVT include sneezing, snoring, difficulty breathing, nasal deformation or bloody or other discharge from the nose or mouth.

Published in Veterinary Record, 'Sex disparity in oronasal presentations of canine transmissible venereal tumour' is available to read here

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.